TWiV 908: COVID-19 clinical update #118 with Dr. Daniel Griffin
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #118, Dr. Griffin discusses management of hair loss after infection, FDA announcements on vaccine schedule and recommendations, Moderna announcement on bivalent booster candidate, association between vaccination and infection during pregnancy, population-level implications of Israel's booster campaign, PAXLOVID outcomes during recent infection surge, efficacy and safety of Tixagevimab-cilgavimab, diagnostic accuracy of infection by canines, efficacy of colchicine in hospitalized patients, and factors associated with hospital readmission.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Management of hair loss after infection (NIH)
- FDA announces vaccine schedule meeting (FDA)
- FDA advisory committee recommends NOVAVAX vaccine (Novavax)
- Moderna announces bivalent booster candidate (Moderna)
- Association of vaccination and infection during pregnancy (JAMA)
- Implications of Israeli booster campaign (Science Translational Medicine)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- PAXLOVID outcomes during infection surge (Research Square)
- Efficacy and safety of Tixagevimab–cilgavimab (The Lancet)
- Diagnostic accuracy of infection by canines (PLOS ONE)
- Efficacy of colchicine in hospitalized patients (Nature)
- Factors associated with readmission (IDSA)
- Contribute to FIMRC fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 908
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]